CustomCustomCustomCustomCustomCustom

home2026-04-16T11:26:48+02:00

biomarkers for more stability in life

Our Mission:
RNA biomarkers for precision medicine

discovery_and_validation_of_microRNA_biomarkers

TAmiRNA is dedicated to supporting researchers and clinicians in RNA biomarker discovery, validation, and development. Our mission is to provide innovative diagnostic solutions that improve patient outcomes, with a focus on precision medicine and age-associated diseases.

TAmiRNA - stability for live

Our Expertise:
RNA signatures and diagnostics

mircoRNA_signatures

We specialize in biomarker discovery using cell-free RNAs, including microRNAs, mRNAs, and long non-coding RNAs (lncRNAs). By integrating RNA signatures with AI-driven analysis, we develop actionable diagnostic solutions that enhance disease detection and patient stratification.

TAmiRNA - stability for live

Our Focus:
biomarker discovery for complex diseases

age_associated_diseases

TAmiRNA drives R&D and contract research in liver disease, senescence, cardiovascular disease, oncology, and bone and joint disorders. Using advanced transcriptomic approaches, we aim to decode disease mechanisms, personalize diagnostics, and accelerate biomarker-driven innovations.

TAmiRNA - stability for live

biomarkers for more stability in life

Our Mission:
RNA biomarkers for precision medicine

discovery_and_validation_of_microRNA_biomarkers

TAmiRNA is dedicated to supporting researchers and clinicians in RNA biomarker discovery, validation, and development. Our mission is to provide innovative diagnostic solutions that improve patient outcomes, with a focus on precision medicine and age-associated diseases.

Our Focus:
biomarker discovery for complex diseases

mircoRNA_signatures

TAmiRNA drives R&D and contract research in liver disease, senescence, cardiovascular disease, oncology, and bone and joint disorders. Using advanced transcriptomic approaches, we aim to decode disease mechanisms, personalize diagnostics, and accelerate biomarker-driven innovations.

Our Expertise:
RNA signatures and diagnostics

We specialize in biomarker discovery using cell-free RNAs, including microRNAs, mRNAs, and long non-coding RNAs (lncRNAs). By integrating RNA signatures with AI-driven analysis, we develop actionable diagnostic solutions that enhance disease detection and patient stratification.

Services

Transcriptomic services

services

Exploring microRNAs, mRNAs, circular RNAs, or other non-coding RNAs?

TAmiRNA offers validated solutions for targeted (RT-qPCR) and untargeted (NGS-based) RNA analysis in serum, plasma, urine, saliva, milk, EVs, exosomes, cells, and tissues. With 11+ years of RNA biomarker expertise, we ensure reliable results and project success.

TAmiRNA - the power of microRNA biomarkers

RNA biomarker services

Interested in our microRNA disease panels or IVD/RUO kits but lack the time or resources for in-house analysis?

Send us your samples, and our in-house services will deliver results for hepatomiR®, senomiR®, toxomiR®, osteomiR®, and thrombomiR®. We also support custom miRNA or mRNA signature analysis by implementing tailored workflows.

TAmiRNA - the power of microRNA biomarkers
Click_here_for_your_personalized_microRNA_service_offer

our services

RNA analysis services

services

You are interested in microRNAs, mRNAs, circular RNAs, as well as other small or long non-coding RNAs?

TAmiRNA offers validated solutions for targeted (RT-qPCR) as well as untargeted (transcriptomic) analysis of any RNA in serum, plasma, urine, saliva, EVs and exosomes, cells, and tissues. Our experience of 11+ years in RNA biomarker development ensure the success of our customer projects.

TAmiRNA - the power of microRNA biomarkers

Kit services

You are interested in our microRNA disease panels or IVD/RUO kits, but don´t have the time or resources to analyse in your lab?

You can send us your samples to obtain results for hepatomiR®, senomiR®, toxomiR®, osteomiR®, or thrombomiR® by taking advantage of our in-house services. In addition, we can support the analysis of your specific miRNA or mRNA signature by implementing a tailored workflow or kit.

TAmiRNA - the power of microRNA biomarkers
TAmiRNA - stability for live

Products

TAmiRNA - stability for live
TAmiRNA - stability for live
TAmiRNA - stability for live

our products

TAmiRNA - stability for live
TAmiRNA - stability for live
TAmiRNA - stability for live

latest news

TAmiRNA @ RNA Leaders Europe Conference

By |March 11th, 2026|Categories: biomarker, circulating miRNAs, Conference, microRNA, microRNA services, NGS, RNA|Tags: , , , , , , , |

Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, [...]

Read More
Comments Off on TAmiRNA @ RNA Leaders Europe Conference

Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

By |March 2nd, 2026|Categories: biomarker, circulating miRNAs, Illumina NewSeq2000, microRNA, microRNA services, NGS, T1D, Type 1 Diabetes|Tags: , , , , , , , , |

TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). [...]

Read More
Comments Off on Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

New white paper with RoosterBio on omics-tools for EV characterization

By |January 21st, 2026|Categories: EV characterization, exosomes, extracellular vesicle, miND, miND spike-in, NGS, sequencing, small RNA-sequencing|Tags: , , , , , , , , |

In this white paper, TAmiRNA and RoosterBio present a comprehensive small RNA-sequencing–based characterization of mesenchymal stem cell (MSC)–derived exosomes produced using RoosterBio’s standardized, xeno-free manufacturing platform. The study was [...]

Read More
Comments Off on New white paper with RoosterBio on omics-tools for EV characterization

TAmiRNA @ RNA Leaders Europe Conference

By |March 11th, 2026|Categories: biomarker, circulating miRNAs, Conference, microRNA, microRNA services, NGS, RNA|Tags: , , , , , , , |

Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the [...]

Read More
Comments Off on TAmiRNA @ RNA Leaders Europe Conference

Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

By |March 2nd, 2026|Categories: biomarker, circulating miRNAs, Illumina NewSeq2000, microRNA, microRNA services, NGS, T1D, Type 1 Diabetes|Tags: , , , , , , , , |

TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). The study, published [...]

Read More
Comments Off on Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

New white paper with RoosterBio on omics-tools for EV characterization

By |January 21st, 2026|Categories: EV characterization, exosomes, extracellular vesicle, miND, miND spike-in, NGS, sequencing, small RNA-sequencing|Tags: , , , , , , , , |

In this white paper, TAmiRNA and RoosterBio present a comprehensive small RNA-sequencing–based characterization of mesenchymal stem cell (MSC)–derived exosomes produced using RoosterBio’s standardized, xeno-free manufacturing platform. The study was designed to assess [...]

Read More
Comments Off on New white paper with RoosterBio on omics-tools for EV characterization
© Copyright TAmiRNA 2019 - 
Go to Top